²Ä¤Q³¹¡GÃĪ« - ¤ã¨º¦Ì³ (Zanamivir)
[
back ]
²¤¶
(ºñ¦â³sµ²:
§K¶O¥þ¤å¾\Äý)
¤ã¨º¦Ì³(Zanamivir)¬O¤@ºØ¤fµÄ§l¤J¯»¾¯¡C²{¦b¦³19Ó°ê®a¤]±Ä¥Î¥¦¬°ªvÀø©Î¹w¨¾¬y¦æ·P«_¥Ò¤Î¤A«¬¯f¬r(influenza
viruses A & B)¤§¥Î¡C¤ã¨º¦Ì³(Zanamivir)¬O¯«¸gÓižJ¿}³J¥ÕªºÄvª§©Ê§í¨î¾¯(neuraminidase
glycoprotein)¡C¯«¸gÓižJ¿}³J¥Õ¦b¬y·P¯f¬r¶i¦æ¤J«I®É¦û«Ü«n§@¥Î¡C¥¦»P³è²G»Ä(sialic
acid)·¥¬Û¦ü¡A¬O¯«¸gÓižJ(neuraminidase)ªº¦ÛµM°ò½è(Varghese
1992, Varghese
1995)¡C
¤ã¨º¦Ì³(Zanamivir)¬O³z¹L§l¤J¤è¦¡¡Aª½±µ¶i¤J©I§l¹D¡C·í¤¤ªº¿@«×«öpºâ¬°¯«¸gÓižJ(neuraminidase)¤§50%§í¨î¿@«×(IC50)ªº1,000¿¡C¦Ó¨ä§í¨î¤ÏÀ³¬°10¶r¤§¤º¡C
·íÃhºÃ¥X²{¨t²Î©Ê¬y·P·P¬V¡A¯S§O¬O³Ìªñ¦³¤HÃþ·P¬V¸V¬y·P(de
Jong 2005)¡A¤ã¨º¦Ì³(Zanamivir)¥i¯à´N¤£¬O¾A¦XªºÃĪ«¡C
¹L¥hªñ´X¦~¡A¥X²{¹L´X©v¦]ªA¥Î¤ã¨º¦Ì³(Zanamivir)«á¡A¥X²{¤ä®ðºÞµjÅË¡B®ð³Ý¡B¬õ¯lëC³Â¯l¤Î¹L±Ó¤ÏÀ³(¦p±¤Î«|³ï¤ô¸~)¡C¤£¹L¡A°£¤F´X©v¨u¨£±¡ªp¥~¡A¦p¦´ÁªA¥Î¤ã¨º¦Ì³(Zanamivir)¤]¬O¦w¥þªº(Hayden
1997)¡C
¦P¤@®É¶¡ªA¥Î¤ã¨º¦Ì³(Zanamivir)¤Îª`®g§C¬¡©Ê¤T»ù¬y·P¬Ì](inactivated
trivalent influenza vaccine)¡A¤@¯ë¤£·|¹ï»s³y§Ü¾®¦å§ÜÅé(antihaemagglutinin
antibodies)²£¥Ít±¼vÅT(Webster
1999)¡C³o¨Ç«OÅ@©Ê§ÜÅé¦h¦b12¤Ñ¤º²£¥Í(Cox
2001)¡C
¤Æ¾Çµ²ºc
¤ã¨º¦Ì³(Zanamivir)¤Æ¾Ç¦WºÙ¬O5-(acetylamino)-4-[(aminoiminomethyl)-amino]-2,6-
anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-en
onic acid¡C¥¦ªºµ²ºcµ{¦¡¦p¤U¡G

ÃĪ«°Ê¤O¾Ç
¸ê®ÆÅã¥Ü¡A¦³10-20%ªº¤ã¨º¦Ì³(Zanamivir)·|³z¹L¤fµÄ§l¤J¨ì¹FªÍ³¡¡C¾l¤Uªº·|¯d¦b«|³ï¡A¤j¬ù4-17%ÃĶq³Q¤HÅé§l¦¬¡C¥Î10²@§J¤§«á¡A¦b1-2¤p®É¤º¡AÃĪ«¦b¦å²G¤¤¹F³Ì°ª¿@«×¡C¦å³J¥ÕÂH¦X³Q¨î(<
10 %)¡C¤ã¨º¦Ì³(Zanamivir)³Ì«á±q§¿²G¤¤±Æ¥X¡A¾ãÓ¹Lµ{¦b24¤p®É¤§¤º(Cass
1999b)¡C¨ä¥b°I´Á¬°2.5-5.1¤p®É¡C
¦³¹êÅç¬ã¨s¤¤¡A·íÀR¯ßª`®g¤ã¨º¦Ì³(Zanamivir)«á¡AÃĪ«¦¨¥÷·|¤À°t¨ì©I§l¹DÂH²G¡A¶i¦Ó¥i¨¾¤î¨ü¬y¦æ·P«_¥Ò¯f¬r(influenza
viruses A )·P¬V(Calfee
1999)¡C
¬r©Ê
°ò¥»¤W¡A¤ã¨º¦Ì³(Zanamivir)¤]¥iºâ¦w¥þ¡A¨ä¤Þ°_©I§l¹D°ÝÃD¾÷·|¤Q¤À§C(Loughlin
2002)¡C¦b¸ÕºÞ´ú¸Õ©Î°Êª«Å餺´ú¸Õ¤¤¡A¤ã¨º¦Ì³(Zanamivir)§t«æ¼@¬r©Ê«Ü§C¡A§Y¨Ï¥Î¤ñ¥¿±`¦h100¿¾¯¶q¡A¤£·|¦³¥ô¦ó©úÅã¥þ¨¤¤¬r¤ÏÀ³¡C¤]¤£¨£©I§l¹D¨ü¨ë¿Eªí²{(Freund
1999)¡C
¤@¯ë«ØÄ³¤ã¨º¦Ì³(Zanamivir)¤§¾¯¶q¡A¬O¤£·|¥O±w¦³©I§l¹D¯e¯f¤§±wªÌ¥X²{°Æ§@¥Î¡C¤£¹L¡A¦³±wªÌ¾ÚºÙªA¥Î¤ã¨º¦Ì³(Zanamivir)«á¡A¥X²{¤ä®ðºÞµjÅˤΪͥ\¯à´î§C(FEV¡A©Î¦y®p©I®ð³Ì°ª¬y³t)¡C¦Ó¦³°ÝÃDӮפ¤¡A³o¨Ç±wªÌ¥»¨¦³¨Ç¼ç¦b©I§l¹D¯e¯f¡A¦pý³Ý©ÎºC©Êªý¶ë©Ê©I§l¹D¯e¯f¡C¥Ñ©ó¥i¯à·|¤Þ°_ÄY«°ÝÃD¡A¬G¦¹¤@¯ë³£¤£«ØÄ³¦³¼ç¦b©I§l¹D¯e¯f¤§±wªÌªA¥Î¤ã¨º¦Ì³(Zanamivir)¡C¤@¯ë±wªÌ¥X²{¤ä®ðºÞµjÅˤΪͰIºÜªº¸Ü¡AÀ³¥ß¨èªA¥Î¤ã¨º¦Ì³(Zanamivir)¡C¦pªG¥X²{ÄY«¼xª¬¡A§óÀ³§Y®É¶i¦æªv²z¤Î°e°|Æ[¹î¡C
¦]¬°ªA¥Î¤ã¨º¦Ì³(Zanamivir)¡A¥X¹L±Ó¤ÏÀ³¥]¬A«|³ï¤ô¸~¤ÎÄY«¥Ö½§¬õ¯l¡A¬O¤Q¤À¨u¨£¡C¸U¤@¯uªº¥X²{¨Ç±¡ªp¡AÀ³¥ß¨è°±¤î¥ÎÃĤγB²z¥Ø«e±¡ªp¡C
¦bªA¥Î¤ã¨º¦Ì³(Zanamivir)²Õ¤ÎªA¥Î¨Å¿}Ãþ¦w¼¢¾¯²Õ¤ñ¸û¡A¨âªÌ¥X²{°Æ§@¥Îªº¦¸¼Æ®t¤£¦h¤¶¥G¤@¼Ë¡C°Æ§@¥Î¥]¬A¡G¸¡Âm¡Bäú¤ß¡BÀY·w¡BÀYµh¡B§íÆ{¡B¸¡µh¡BëC³Â¯lµ¥¡C³Ì¦h¥X²{¹êÅ礣¥¿±`§¡¬O¦b²Ä¤T´ÁªvÀø¬ã¨s¡A¥]¬A¡G¨xžJ¯À¤W¤É¡BCPK¡B²O¤Ú²y´î¤Ö¤Î§C¶Ý¤¤©Ê²y(neutropenia)¡C¦P¼Ë¡A¦b¹êÅç©Î¨Å¿}¦w¼¢¾¯²Õ§O©Ò¥X²{«æ©Ê¬y·P¼xª¬ªº¦¸¼Æ¤]®t¤£¦h(Relenza
2003)¡C
¬Û¤Ï¡A¹ï©ó5-12·³¨àµ£¨Ó»¡¡A¥X²{»ó³¡¯f¼x(¤ã¨º¦Ì³(Zanamivir)
20 %, ¦w¼¢¾¯9 %)¡B«y¹Â(¤ã¨º¦Ì³(Zanamivir) 16 %, ¦w¼¢¾¯8
%)¤Î«|³ï¤£¾A(¤ã¨º¦Ì³(Zanamivir) 11%, ¦w¼¢¾¯6%)¡A»¡©ú¤FªA¥Î¤ã¨º¦Ì³(Zanamivir)¤Þ°_°Æ§@¥Îªº¾÷·|¤ñªA¥Î¦w¼¢¾¯¸û¦h¡C¦ÓºC©Ê©I§l¹D¯e¯f¤è±¡A¥X²{¤U©I§l¹D¤£¨}¤ÏÀ³¥]¬Aý³Ý¡B«y¹Â©Î¯f¬r©Ê©I§l¹D·P¬Vµ¥Ãþ¦ü¬y·P¼xª¬¡A®t¤£¦h¥þ³¡7Ӥ㨺¦Ì³(Zanamivir)ªA¥ÎªÌ¤]¥X²{¥H¤W¤£¨}¤ÏÀ³¡A¹ï¤ñ12Ó¦w¼¢¾¯ªA¥ÎªÌ¥u¦³5Ó¥X²{¥H¤W±¡ªp¡C
¥H¤Uªº¤£¨}¤ÏÀ³Ó®×¬O¤ã¨º¦Ì³(Zanamivir)±À¥X¥«±«á©Ò¦¬¶°¦^¨Ó¡C¦ý¬O·í¤¤ªº¼Æ¾Ú¤Î¬O§_¯uªº»P¤ã¨º¦Ì³(Zanamivir)¦³Ãö¡A²{¤´¥¼ªÖ©w(Relenza
2003)¡G
- ¹L±Ó¤ÏÀ³¡A¥]¬A«|³ï¤ô¸~
- ¤ß«ß¥¢±`¡A ·w³Ö
- ¥|ªÏ©âÝz
- ¤ä®ðºÞµjÅË¡A®ð³Ý
±q¥¼°µ¹L¦³Ãö¥¥°ü¹ï¤ã¨º¦Ì³(Zanamivir)¤ÏÀ³¬ã¨s¡C¦b°Êª«¹êÅ礤¡A¤ã¨º¦Ì³(Zanamivir)¥¼¨£¯à¾ÉP¬y²£©Î¨ä¥L°ÝÃD¡C
¦b¤j¦Ñ¹«¨¤W¡Aµo²{¤ã¨º¦Ì³(Zanamivir)¯à±q¨Å²G±Æ¥X¡A¦ý¥¼¦³¦b¤HÅé°µ¹LÃþ¦ü¹êÅç¡A¬G¤´¨S¦³¸ê®ÆÅã¥Ü¤ã¨º¦Ì³(Zanamivir)¯à¦b¤HÃþ¨Å²G¤¤±Æ¥X¡C
®Ä¯à
¦pªG¦b¬y·Pµo¯f«á48¤p®É¤º§l¤J¤ã¨º¦Ì³(Zanamivir)¡A¯à´î¤Ö¨ä¥X²{¼xª¬®É¶¡¦Ü2.5¤é¡C¤ã¨º¦Ì³(Zanamivir)ªº¦n³B¦ü¥G¦b¨º¨Ç¯f«±wªÌ(¦p¦³¼ç¦b©Î°ª¦M¯e¯f)©Î¦~¦Ñ±wªÌ(≥50·³)§ó©úÅã¡C¬Û¤Ï¡A¹ï©ó¤@¨Ç©¿¸û§C·Å©Î¯f±¡¸û»´ªº±wªÌ¡A¤ã¨º¦Ì³(Zanamivir)°_ªº§@¥Î´N¤£ºâ¤j¡C
¥Î©ó¹w¨¾¤è±¡A¥H¨Ï¥Î¦w¼¢¾¯¤ñ¸û¡A¤ã¨º¦Ì³(Zanamivir)©úÅã¯à´î¤Ö®a®x¥X²{¬y·P¼xª¬¡A¥ç¥i´î¤ÖÀø¾i°|¥X²{¬y·PӮסC
ªvÀø
º¦¸¹ï¤ã¨º¦Ì³(Zanamivir)§@Á{§É¬ã¨s¡A¬O¦b1994-1995¦~¡A¥_¬ü38¤¤¤ß¤Î¼Ú¬w32¤¤¤ß¡A¥HÀH¾÷¤ÎÂùª¼¹êÅç¤èªk¡A¹ï¯f¤H¤ÏÀ³§@¥X¤ÀªR¡C¦b¬ã¨s¤¤¡A¤j¬ù¯à´î»´¬y·P¼xª¬¤@¤éªº®É¶¡(4
vs. 5¤é) (Hayden
1997)¡C¦ÓÀò±o¸û¤jªvÀø±o¯q¬O¶}©lÀøµ{®É¤w¥X²{ÄY«¼xª¬ªº±wªÌ(Monto
1999)¡CÆ[¹î50?¥H¤W±wªÌ¥iÀò3¤éÀøµ{±o¯q¡A¦ÓÆ[¹î50·³¥H¤U±wªÌ«h¥iÀò1¤éÀøµ{±o¯q¡Cµo²{°ª¦M±wªÌ¤§ªvÀø±o¯q¬°2.5¤é(Monto
1999)¡C¥[¤W¡A¤ã¨º¦Ì³(Zanamivir)¹ï©ó®e©ö¥X²{¬y·P¨Öµo¯g¤§±wªÌ¤]¦³®Ä¡A¦p¦~¬ö≥65·³¡BºC©Êªý¶ë©Ê©I§l¹D¯e¯f¡B¤ßŦ¯f¡B¿}§¿¯f¤Î§K¬Ì¥\¯à»Ùê(Lalezari
2001)¡C
¬y·P·P¬V¤@¯ë¯à¤Þ°_©I§l¹D¨Öµo¯g¡A¦h±Ä¥Î§Ü¥Í¯ÀªvÀø¡C¥H²Î¦X¤ÀªRmeta-analysis¤èªk¶i¦æ7ºØÁ{§É´ú¸Õ¡A¦]¨Ï¥Î¦w¼¢¾¯«á¦Ó»Ý§Ü¥Í¯ÀªvÀø¨Öµo¯g(¥]¬A«æ©Ê¤ä®ðºÞª¢¡B«æ©Ê»óÄuª¢)¦³17%¡F¦Ó¨Ï¥Î¤ã¨º¦Ì³(Zanamivir)«á¦Ó»Ý§Ü¥Í¯ÀªvÀø¨Öµo¯g¥u¦³11%(Kaiser
2000b)¡C¬Û¤Ï¡A³oӼƾڤ´¥¼¸g¬dÃÒ¡C¥t¥~¤@Ó¤j«¬¨üºÊ±±ªºÁ{§É¬ã¨s¡A¦³¦h©ó2,300¯f¤H°Ñ¥[¡A¦Ó¨Ï¥Î¤ã¨º¦Ì³(Zanamivir)ªº²Õ§O¤Î¦w¼¢¾¯²Õ¡A¨âªÌ©Ò¥X²{¨Öµo¯g¼Æ¦r¤]®t¤£¦h(Cole
2002)¡C
¹w¨¾
¤@³s¦êªºÀH¾÷¸ÕÅç¡AÃÒ©ú¤F¤ã¨º¦Ì³(Zanamivir)ªº½T¹ï¹w¨¾¬y·P¦³®Ä¡C¦b¹êÅ礤¡A°·±d¦¨¤H·í¥X²{¬y·PÃzµo«á¡A¤©¤fµÄ§l¤J¨C¤é10²@§J¤ã¨º¦Ì³(Zanamivir)©Î¦w¼¢¾¯¡A¬°´Á4Ó¬P´Á¡Aµo²{ªñªA¥Î¤ã¨º¦Ì³(Zanamivir)ªº¦³67%¹F¬y·P¹w¨¾®ÄªG(6
% [34/554] ¦w¼¢¾¯²Õ§O¥X²{¬y·P¼xª¬vs. 2 % [11/553] ¤ã¨º¦Ì³(Zanamivir)²Õ§O¥X²{¬y·P¼xª¬)¡A¤Î¦³84%
¯à¨¾¤î¥X²{µo¿N¼xª¬(Monto
1999b)¡C
¥t¤@ÓÁ{§É¹êÅç¡A¯A¤Î2-5¤Hªº®a®x¡A·í¤¤¦Ü¤Ö¦³¤@Ó5?¤j¤pµ£¡C·í¦³¨ä¤¤¤@Ó®a®x¦¨û±w¦³¬y·P«á¡A¥þ®a¤H»ÝªA¥Î10²@§J¨C¤é¤ã¨º¦Ì³(Zanamivir)©Î¦w¼¢¾¯¡A¬°´Á10¤é¡Cµ²ªGÅã¥Ü¡AªA¥Î¤ã¨º¦Ì³(Zanamivir)ªº®a®x¤¤¥u¦³4%¥X²{·s¬y·PӮסF¬Û¤Ï¡AªA¥Î¦w¼¢¾¯ªº®a®x®t¤£¦h¦³19%¥X²{·s¬y·PӮסCªA¥Î¤ã¨º¦Ì³(Zanamivir)ªº©Ò¥X²{¼xª¬®É¶¡¬°2.5¤é¡A¸ûªA¥Î¦w¼¢¾¯ªº¬°µu(5-7.5¤é)
(Hayden
2000)¡C¦Ó¥t¤@¬ã¨s¡A¦P¼Ë¬OªA¥Î¤ã¨º¦Ì³(Zanamivir)«á¡A¥ç´î¤Ö¦]±µÄ²¬y·PÃþ¦üӮצӱw¤W¬y·P¤§¾÷·|(Kaiser
2000)¡C
¦³¤@¬ã¨sµ²ªGÅã¥Ü¡AªA¥Î¤ã¨º¦Ì³(Zanamivir)ªº®a®x¤¤¥u¦³4%¥X²{·s¬y·PӮסF¬Û¤Ï¡AªA¥Î¦w¼¢¾¯ªº®a®x®t¤£¦h¦³19%¥X²{·s¬y·PӮסC»¡©ú¨ä¹w¨¾®Ä¯à¹F81%¡C¦Ó¹ï©óÓ§O¤§¹w¨¾®Ä¯à°ª¹F82%¡A¤Î¹ï©ó¥Ò¡B¤A«¬¬y·P¤§¹w¨¾®Ä¯à¤À§O¬°78%¤Î85%
(Monto
2002)¡C
¨àµ£
¦b¬ã¨s¹êÅ礤¡A¿ï¨ú¤F¦~ÄÖ¤¶¥G5-12·³¡C¦P¼ËªA¥Î¤ã¨º¦Ì³(Zanamivir)ªº±o¯q¬°©Ò¥X²{¼xª¬¤¤¦ì¼Æ®É¶¡´î¤Ö1.25¤é¡A¥[¤W¨ä¯f·U®É¶¡¸ûµu¤Î¥ÎÃĪ«¥÷¶q¸û»´(Hedrick
2000)¡C
¦]¦¹¡A¤ã¨º¦Ì³(Zanamivir)¹ï©ó¨àµ£¬O¦w¥þ¡A¦p¥L̯àªA¥Î¥¦¡C¨àµ£¡A¯S§O¬O¢··³¥H¤Uªº¡A³q±`¤£¯à¨Ï¥ÎÄÀ©ñ¤ã¨º¦Ì³ªº¨t²Î¡e¥]¬A¤£¯à°µ¦¨¨¬°÷¶q«×ªº§l¤J²v©Î¹F¨ì¾A·íªº¦y®p§l®ð¬y³t¡]§Y§C©ó¨C¤ÀÄÁ¢µ¢¯¤½¤çªº³Ì²z·Q³t«×¡^¡f¡C¦b¯Ê¥F¨ä¥i¶q«×¤§§l¤J²v¥HP¤£¨¬°÷©Î¦å²M¤£¯à¶q«×¿@«×¡A°tÃÄû¦Ò¼{¥ÎÃÄ®ÉÀ³¤p¤ß¤ÀªR¨àµ£¨Ï¥Î§l¯Ç¾¹¤§¯à¤O¡C·í¯u¥¿¥Î©ó¨àµ£ªº®É«J¡A¤@©wn¦³¦¨¤HºÊ·þ¤Îª`µ£¾A·íªº¨Ï¥Î§l¯Ç¾¹(Relenza
2003)¡C
¯S®í±¡ªp
¹ï©ó±w¦³«æ©Ê²O¤Ú²ÓM¥Õ¦å¯f(acute lymphoblastic leukemia)
(Maeda
2002)¤Î´¿¶i¦æ¹L²§Åé·F²ÓM²¾´Ó(allogeneic stem cell transplantation)
(Johny
2002)¤§±wªÌ¡A¨äªA¥Î¤ã¨º¦Ì³(Zanamivir)¤§¾¯¶qn¯S§O³B²z¡C¦b²Ä¤GÓ³ø§i«ü¥X¡A¤ã¨º¦Ì³(Zanamivir)¤£·|¥X²{¬r©Ê¤ÏÀ³¡C¥ç¨S¦³¥X²{¹L³oÃþ¯f¤H¦]¬V¤W¬y·P¦º¤`ªº¯f¨Ò¡C
¸V¬y·P¯f¬r
¦b2000¦~´¿¶i¦æ¹L¦³Ãö¤ã¨º¦Ì³(Zanamivir)¹ï¬y·P¯f¬rµ¥¦Ñ¹«¹êÅç¡Aµo²{¤ã¨º¦Ì³(Zanamivir)¹ï©óH9N2,
H6N1¤Î´¿¥X²{÷¨ÅÃþ·P¬VH5N1µ¥¯f¬r¦³©úÅã®Ä¥Î(Leneva
2001)¡C
§ÜÃÄ©Ê
¥X²{§ÜÃĩʤÏÀ³¤ñ¸û¨u¨£¡C¥Ø«e¬°¤î¡A±q§K¬Ì¬¡©Êªº¯f¤H¤´¥¼¹jÂ÷±o¨ì§ÜÃĩʪº¯f¬r¡C¥[¤W¡A©Ò¦³¦b¸ÕºÞ¤¤¨ú±oªº§Ü¤ã¨º¦Ì³(Zanamivir)¯f¬rªº¬¡°Ê©Ê«Ü®z¡C¤w¬°¤H»{ÃѪº§ÜÃĩʬðÅܬO¹ï©ó¬Y¨Ç¯f¬r¨È¸s(virus
subtype)¤ÎÃĪ«¦³¯S²§©Êªº(drug specific) (McKimm-Breschkin
2003)¡C
²{¦b¡A¥ç¦³¨ÇÃÒ¾Ú»¡©ú¦bÁ{§É®É¡A¯«¸gÓižJ§í¨î¾¯(neuraminidase inhibitors)¤§¶¡¡A·|¤Þ°_¤£¦PºØÃþªº§ÜÃÄ«~ºØ¤Î¹ï¤£¦Pªº§í¨î¾¯¦³¥æ¤e¹ï§Üªº¯f¬r¡C
ÃĪ«¬Û¤¬§@¥Î
¤ã¨º¦Ì³(Zanamivir)¬O³z¹L¤fµÄ§l¤J¡A«Ü¤ÖÃĪ«¦¨¥÷¥i¶i¤J¦å²GùØ¡A©Ò¥Hµ²ªG¬O¦å¼ßªºÃĪ«¿@«×«Ü§C¤Î¥þ¨¹ïÃĪ«ªº±µÄ²¤]¬O´¶³qªº¡C¥Ñ©ó¤ã¨º¦Ì³(Zanamivir)¤£³Q¥NÁ¤À¸Ñ¡A¥ç«Ü¤Ö¾÷·|¥X²{ÃĪ«»PÃĪ«¤§¶¡ªº¬Û¤¬§@¥Î(Cass
1999b)¡C¤ã¨º¦Ì³(Zanamivir)¤S¤£¬O°ò½è(substrate)¡A¬G¤£·|¼vÅT¨ì¨xŦ·L²ÉÅé(liver
microsomes)¤¤²ÓM¦â¯ÀP450 (cytochrome P450¡ACYP)¡B¦P¤užJ(isoenzymes
¡ACYP1A1/2, 2A6, 2C9, 2C18, 2D6, 2E1, and 3A4)
(Relenza 2003)¡C ³oùبS¦³²z½×°ò¦»¡©ú¤ã¨º¦Ì³(Zanamivir)·|»P¨ä¥L¤Æ¦Xª«²£¥Í¥NÁ¬ۤ¬§@¥Î(Daniel
1999)¡C
«ØÄ³¥Îªk
- ¤ã¨º¦Ì³(Zanamivir)¤@¯ë¾A¥Î©ó¦¨¤H©Î¨àµ£(¼Ú·ù:12·³©Î¥H¤W¡F¬ü°ê:7·³©Î¥H¤W)¦]¬V¤W¬y·P¥Ò¤Î¤A¯f¬r(influenza
A and B)¡A¥X²{¨Ç«D½ÆÂø©Ê«æ©Ê¼xª¬¡Aµo¯f®É¶¡¤£¨¬2¤Ñ¡C
- ¤ã¨º¦Ì³(Zanamivir)¤£«ØÄ³¥Î©ó±w¦³¼ç¥ñ©Ê©I§l¹D¯e¯f¤§±wªÌ(¦pý³Ý©ÎºC©Êªý¶ë©Ê©I§l¹D¯f,COPD)¡C
¤ã¨º¦Ì³(Zanamivir) (Relenza?)»Ý¥Î¤fµÄ§l¤J¡A¦]¬°¥Î¤fªAªº¥ÍÅé¥i§Q¥Î«×(bioavailability)«Ü§C¡CRelenza?¬°±Û¹FºÐ¡]Rotadisk¡^¾¯«¬¡A¨CÓ±Û¹FºÐ§t¦³4ÓÂù±¿üºäªwÅn¡A¨CÓªwÅn§t¦³¤ã¨º¦Ì³(Zanamivir)
5 ²@§J(¨Ã¥[¤J20²@§J¨Å¿})¡C¨CÓªwÅn¨Ï¥Î³£»Ý³z¹L¤@Ó½¦ª¬»ö¾¹¡AºÙºÐ¦¡§l¯Ç¾¹(Diskhaler)¡C
·íªwÅn³Q¨ë¬ï«á¡A¤ã¨º¦Ì³(Zanamivir)´²¦bªÅ®ð¤¤¡A¥Ñ¯f¤H¤fùظg§l¯Ç¾¹§l¤JÅ餺¡C¦Ü©ó¡A¦³¦h¤ÖÃĪ«¥÷¶q¨ì¹F©I§l¹D¡A§¡µø¥G§l®ð³t«×¡C
±wªÌ¥²¶·¸òÀH«ü¥ÜªAÃÄ¡A¨C±i«ü¥Ü¤]¦³¨Ï¥Î¥Ü½d¡C¦Ó¹ï©ó¨àµ£±wªÌ¡AÀ³¸Ó¦b¦¨¤H«ü¾É¤U¤Î¸òÀH«ü¥ÜªAÃÄ¡C
³oùئҼ{¨ì¤@¯ë¦Ñ¦~¤H¨Ï¥Î§l¯Ç¾¹ªº¯à¤O¡C´N¦¹°ÝÃD¡A´¿¦bÂå°|ùئV73¯f¤H(¦~ÄÖ¤¶¥G71-99·³)°µ¹L½Õ¬d¡Aµo²{¤j³¡¥÷¦~¦Ñ¤H¤h¨Ï¥Î§l¯Ç¾¹¥X²{°ÝÃD¡A¼vÅT¤ã¨º¦Ì³(Zanamivir)ªvÀø¦¨®Ä(Diggory
2001)¡C
¾¯¶q
¦¨¤H¤Î7·³¥H¤W¨àµ£¤§«ØÄ³¾¯¶q¬°10²@§J¨C¤é2¦¸(³sÄò§l¤J¨âÓªwÅn)¡A¬°´Á5¤Ñ¡C
Àøµ{²Ä¤@¤é¡A¥ÎÃĮɶ¡¦Ü¤Ö¹j2¤p®É¤@¦¸¡CÄ~«á¡A®É¶¡¬°¹j12¤p®É¤@¦¸¡C
¹ï©ó±w¦³µÇ¯f±wªÌµL»Ý½Õ¾ã¥ÎÃľ¯¶q(Cass
1999a)¡C
¦pªG¦]ªA¥Î¤ã¨º¦Ì³(Zanamivir)¡A¦Ó¥X²{©I§l¹B§@¥¢½Õ¡AÀ³¥ß¨è¨Ï¥Î§Ö³t®ðºÞÂX±i¾¯¤Î°±¤î¨Ï¥Î¤ã¨º¦Ì³(Zanamivir)¡C
Á`µ²
°Ó¼Ð¦WºÙ¡GRelenza®
ÃĪ«ºØÃþ¡G¯«¸gÓižJ§í¨î¾¯
»s³y°Ó¡GGlaxoSmithKline
«ü¥Ü¡G¤ã¨º¦Ì³(Zanamivir)¤@¯ë¾A¥Î©ó¦¨¤H©Î¨àµ£(¼Ú·ù:12·³©Î¥H¤W¡F¬ü°ê:7·³©Î¥H¤W)¦]¬V¤W¬y·P¥Ò¤Î¤A¯f¬r(influenza
A and B)¡A¥X²{¨Ç«D½ÆÂø©Ê«æ©Ê¼xª¬¡Aµo¯f®É¶¡¤£¨¬2¤Ñ¡C
¼Ð·ÇªvÀø¾¯¶q¡G10²@§J¨C¤é2¦¸(³sÄò§l¤J¨âÓ¤²@§JªºªwÅn)¡A¬°´Á5¤Ñ¡C
¼Ð·Ç¹w¨¾¾¯¶q¡G¦b¤j¦h¼Æªº°ê®a¡A¥ç¥¼§åã¥H¤ã¨º¦Ì³(Zanamivir)§@¹w¨¾§@¥Î¡C
ÃĪ«°Ê¤O¾Ç¡G¦Ê¤À¤§¤Q¦Ü¤G¤Qªº¤ã¨º¦Ì³(Zanamivir)·|³z¹L¤fµÄ§l¤J¨ì¹FªÍ³¡¡A¾l¤Uªº·|¯d¦b«|³ï¡A¤j¬ù4-17%ÃĶq³Q¤HÅé§l¦¬¡C¦b1-2¤p®É¤ºÃĪ«¦b¦å²G¤¤¹F³Ì°ª¿@«×¡C¦å³J¥ÕÂH¦X³Q¨î(<
10 %)¡C¤ã¨º¦Ì³(Zanamivir)³Ì«á±q§¿²G¤¤±Æ¥X¡A¨ä¦å½Ð¥b°I´Á2.5-5.1¤p®É¡C
ĵ§i¡G¤£«ØÄ³¥Î¤ã¨º¦Ì³(Zanamivir)©ó±w¦³¼ç¥ñ©Ê©I§l¹D¯e¯f¤§±wªÌ(¦pý³Ý©ÎºC©Êªý¶ë©Ê©I§l¹D¯f,COPD)¡C
¬Û¤¬§@¥Î¡G®Ú¾Ú¦b¸ÕºÞ¤¤ªº¹êÅç¬ã¨s¡A¦ôp¤ã¨º¦Ì³(Zanamivir)¤£·|¤Þ°_©úÅãÃĪ«¬Û¤¬¤ÏÀ³¡C
°Æ§@¥Î¡G¤ã¨º¦Ì³(Zanamivir)Äݸû¦w¥þÃĪ«¡A¤jÅé¤W¨ä¤Þ°_©I§l¹D¤£¨}¤ÏÀ³ªº¾÷·|«Ü²Ó¡C
±wªÌ¸ê®Æ¡G¨Ï¥Î¤ã¨º¦Ì³(Zanamivir)§@¬°ªvÀø¤§¥Î«á¡A¨S¦³¨£¬y·P¶Ç¬V¥L¤H¤§¾÷·|´î¤Ö¡C
¥ç¦³¤Þ°_¤ä®ðºÞµjÅ˪º¾÷·|¡A¯S§O¬O±w¦³¼ç¥ñ©Ê©I§l¹D¯e¯f¤§±wªÌ¡C¦p¦³©I§l¹D¼xª¬¥[«(¦p³Ý®ð¡B©I§l§xÃø©Î¦³¤ä®ðºÞµjÅË¥ý¥ü)¡AÀ³¥ß¨è°±¥Î¤ã¨º¦Ì³(Zanamivir)¨Ã§äÂå¥ÍÀˬd¡C±w¦³ý³Ý©ÎºC©Êªý¶ë©Ê©I§l¹D¯f(COPD)¤§±wªÌÀ³¯S§Oª`·N¡A¤Î¦³¨Ï¥Î§Ö³t¤ä®ðºÞÂX±i¾¯¤§»Ýn¡C
¦p±wªÌ»Ý¦P®É¨Ï¥Î¤ã¨º¦Ì³(Zanamivir)¤Î§Ö³t¤ä®ðºÞÂX±i¾¯ªº¸Ü¡A«ØÄ³¥ý¨Ï¥Î§Ö³t¤ä®ðºÞÂX±i¾¯¤~§l¤J¤ã¨º¦Ì³(Zanamivir)¡C
¶JÂÃÃĪ«³Ì¦n©ó25¢X C (77¢X F)¡Aµuµ{¥i¦b©ñ¦b15¢X¦Ü30¢X C (59¢X to
86¢X F)¤§¶¢¡C
¤¬Ápºô¨Ó·½¡G
¬ü°ê¡G http://influenzareport.com/link.php?id=5
|